Others have suggested that the pathological effect of IL‐22 in chronic HBV liver injuries may be due to the activation of IL‐22BP, an inhibitor of IL‐22 preventing the binding with IL‐22R1 and IL‐10R1.133 This effect could be abrogated by blocking IL‐22BP to promote resolution of inflammation.133 It has been postulated that this activation may be the cause of a number of failed attempts to use IL‐22 injections as a treatment for hepatic inflammation. This evidence concerns the gene IL22 and inflammatory response.